, WHO. WHO j Data and statistics. Geneva: WHO, 2013.

, Geneva: World Health Organization, WHO. WHO j Consolidated ARV guidelines 2013, 2013.

S. Eholié, F. Aoussi, I. S. Ouattara, E. Bissagnéné, and X. Anglaret, HIV treatment and care in resource-constrained environments: challenges for the next decade, J Int AIDS Soc, vol.15, issue.2, p.17334, 2012.

U. Kaiser, UNAIDS study finds no real change in donor funding for HIV, 2013.

F. Orsi, D. 'almeida, and C. , Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries, Curr Opin HIV AIDS, vol.5, pp.237-278, 2010.

, Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization, 2009.

B. Waning, W. Kaplan, M. P. Fox, M. Boyd-boffa, A. C. King et al., Generic Med, vol.7, pp.159-75, 2010.

B. Waning, W. Kaplan, A. C. King, D. A. Lawrence, H. G. Leufkens et al., Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases, Bull World Health Organ, vol.87, pp.520-528, 2009.

C. V. Chien, HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare? PLoS One, vol.2, p.278, 2007.

S. Lucchini, B. Cisse, S. Duran, C. Comiti, M. Gaudry et al., Decrease in prices of antiretroviral drugs for developing countries: from political ''philanthropy'' to regulated markets, Issues and challenges. France: ANRS, pp.169-211, 2003.

V. J. Wirtz, S. Forsythe, A. Valencia-mendoza, and S. Bautista-arredondo, Factors influencing global antiretroviral procurement prices, BMC Public Health, 2009.

:. S6 and . Doi,

C. Meiners, L. Sagaon-teyssier, L. Hasenclever, and J. Moatti, Modeling HIV/AIDS medicine price determinants in Brazil: is generic competition a myth?, PLoS One, vol.6, p.23478, 2011.

B. Waning, M. Kyle, E. Diedrichsen, L. Soucy, J. Hochstadt et al., Global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets, Global Health, vol.6, p.9, 2010.

J. Dumoulin, M. Kaddar, and G. Velásquez, Guide d. analyse e ´conomique du circuit du médicament' Genè ve: Organisation mondiale de la Santé, 2001.
URL : https://hal.archives-ouvertes.fr/hal-00851040

T. Dickens, The world medicines situation 2011. Geneva: World Health Organization, 2011.

. Medicines-patent and . Pool, UNAIDS. Doha'10 trips flexibilities and access to antiretroviral therapy: lessons from the past, opportunities for the future. Geneva: UNAIDS; 2011. 18. UNAIDS. Implementation of TRIPS and access to medicines for HIV after, strategies and options for least developed countries, vol.17, 2011.

N. Judice, O. Zaglada, R. Mbuya-brown, and . Hiv, Health Policy Project, 2011.

E. Seoane-vazquez and R. Rodriguez-monguio, Good practice guide: improving access to treatment by utilizing public health flexibilities in the WTO TRIPS agreement, Health Policy Plan, vol.22, pp.63-72, 2007.

A. Castro and M. Westerhaus, Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements, Cad Saude Publica, vol.23, 2007.

E. Bendavid and E. Leroux, The relation of price of antiretroviral medicines and foreign assistance with coverage of HIV treatment in Africa: retrospective study, J Econ Perspect, vol.341, pp.45-66, 2002.

T. L. Regan, Generic entry, price competition, and market segmentation in the prescription medicine market, Int J Ind Organ, vol.26, pp.930-978, 2008.

D. Reiffen and M. Ward, Generic medicine industry dynamics, Rev Econ Stat, vol.87, issue.1, pp.37-49, 2005.

M. Kyle and A. Mcgahan, Investments in pharmaceuticals before and after TRIPS, Rev Econ Stat, vol.94, issue.4, pp.1157-72, 2012.

L. Sagaon-teyssier, Journal of the International AIDS Society, vol.19, 2016.

*. ,

, Gross National Income per capita) 0.1649*** (0.1399, 0.1900) 0.0698*** (0.0616, 0.0781) log(Quantity purchased per transaction, Sub-Saharan Africa log

L. Sagaon-teyssier, Journal of the International AIDS Society, vol.19, 2016.

*. , 3396) Ref: B5 years Number of observed suppliers (0.0266***

, World Bank classification of developing regions; b given that the dataset used in the study comprises transactions from 2003 to 2nd quarter 2015, the therapeutic class accounts for the changes in WHO guidelines (time-varying variable); c as suggested by the polynomial regression technique, exponents were introduced until the estimated coefficients are not significant

L. Sagaon-teyssier, Journal of the International AIDS Society, vol.19, 2016.